

**VEGF R3/FLT4**  
**Catalog # PVGS1818****Specification**

---

**VEGF R3/FLT4 - Product Information**

Primary Accession [P35916-1](#)  
**Species**  
Human

**Sequence**  
Tyr25-Ile776

**Purity**  
> 95% as determined by Bis-Tris PAGE  
> 95% as determined by HPLC

**Endotoxin Level**  
Less than 1EU per µg by the LAL method.

**Biological Activity**  
Immobilized Human VEGF-C, His Tag at 5 µg/ml (100 µl/Well) on the plate can bind VEGF R3/FLT4[Biotin], His&Avi, Human (Cat.No.: Z03971)

**Expression System**  
HEK293

**Theoretical Molecular Weight**  
87.4 kDa

Formulation **Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).**

**Reconstitution**  
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH<sub>2</sub>O more than 100 µg/ml.

**Storage & Stability**  
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

**VEGF R3/FLT4 - Additional Information**

**Target Background**  
Vascular endothelial growth factor receptor 3 (VEGFR3) is one kind of tyrosine-protein kinase. VEGFR3 acts as a cell-surface receptor for VEGFC and VEGFD. It is a key regulator of lymphatic system development and establishment. VEGFR3 plays important roles in angiogenesis. It is also up-regulated in the endothelium of blood vessels in breast cancer and various other tumors.

**VEGF R3/FLT4 - Protein Information**

## **VEGF R3/FLT4 - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

## **VEGF R3/FLT4 - Images**